Back close

Cetuximab Conjugated O-carboxymethyl Chitosan Nanoparticles for Targeting EGFR Overexpressing Cancer Cells

Publication Type : Journal Article

Thematic Areas : Nanosciences and Molecular Medicine

Publisher : Carbohydrate Polymers

Source : Carbohydrate Polymers, Volume 93, Number 2, p.661-669 (2013)

Url :

Keywords : Antibodies, antineoplastic agent, Antineoplastic Agents, Antitumor, article, Biological, Carboxymethyl chitosan, Cell death, Cell Line, Cetuximab, chemistry, chitosan, Drug delivery, drug delivery system, Drug Delivery Systems, drug derivative, drug effect, drug screening, Drug Screening Assays, EGFR, Electron, Epidermal Growth Factor, epidermal growth factor receptor, erythrocyte, Erythrocytes, flow cytometry, gelation, Hemolysis, human, Humanized, Humans, Medical nanotechnology, metabolism, methodology, microscopy, Monoclonal, Monoclonal antibodies, monoclonal antibody, nanoparticle, Nanoparticles, Nanotechnology, O carboxymethylchitosan, O-carboxymethylchitosan, Oncology, oxazine derivative, Oxazines, paclitaxel, particle size, Pharmaceutical, Receptor, resazurin, Scanning, scanning electron microscopy, Targeted drug delivery, Tumor, tumor cell line, tumor marker, Tumor Markers, ultrastructure, xanthene derivative, Xanthenes

Campus : Kochi

School : Center for Nanosciences

Center : Amrita Center for Nanosciences and Molecular Medicine Move, Nanosciences

Department : Nanosciences and Molecular Medicine

Year : 2013

Abstract : Nanoparticle mediated delivery of antineoplastic agents, functionalized with monoclonal antibodies has achieved extraordinary potential in cancer therapy. The objective of this study was to develop a drug delivery system comprising O-carboxymethyl chitosan (O-CMC) nanoparticles, surface-conjugated with Cetuximab (Cet) for targeted delivery of paclitaxel (PTXL) to Epidermal Growth Factor Receptor (EGFR) over-expressing cancer cells. Nanoparticles around 180 ± 35 nm and negatively charged were prepared through simple ionic gelation technique. The alamar blue assay indicated that these targeted nanoparticles displayed a superior anticancer activity compared to non-targeted nanoparticles. The nanoformulation triggered enhanced cell death (confirmed by flow cytometry) due to its higher cellular uptake. The selective uptake of Cet-PTXL-O-CMC nanoparticles by EGFR +VE cancer cells (A549, A431 and SKBR3) compared to EGFR -VE MIAPaCa-2 cells confirms the active targeting and delivery of PTXL via the targeted nanomedicine. Cet-PTXL-O-CMC nanoparticles can be used a promising candidate for the targeted therapy of EGFR over expressing cancers. © 2012 Elsevier Ltd.

Cite this Research Publication : S. Maya, Kumar, L. G., Sarmento, B., N. Rejinold, S., Dr. Deepthy Menon, Nair, S. V., and Dr. Jayakumar Rangasamy, “Cetuximab Conjugated O-carboxymethyl Chitosan Nanoparticles for Targeting EGFR Overexpressing Cancer Cells”, Carbohydrate Polymers, vol. 93, pp. 661-669, 2013.

Admissions Apply Now